Precision Business Insights

Portfolio

Research Reports

SELECT LICENSE TYPE
Databank $ 2,000.00
spinner
Single User $ 3,000.00
spinner
Multiple User $ 4,000.00
spinner
Corporate User $ 6,000.00
spinner
buy now spinner

Why Precision Business Insights?

  • Pre and Post Sale Support

    Get in touch with our industry experts to resolve your research queries before and after buying the report. Avail free 60 minutes analyst tele-call to get additional market information before and after purchase

  • Special Pricing and Discounts

    Avail special pricing for the purchase of report sections,regional insights, and historical data. Discounts for government bodies, research institutes, universities, NGO’s and start-up’s

  • In-depth Market Analysis

    Our research reports provides holistic market information with 360 degree analysis. We adopt 3 pronged strategy to analyze the market i.e. Secondary research , primary research, and expert validation

  • Accurate and Reliable Market Data

    Utmost focus on delivering accurate and reliable research reports. We adopt internally developed data mining tools to eliminate any data errors

  • NICHE AND GROWTH MARKETS EXPERTISE

    Proven expertise in delivering new and emerging markets product and technology advancements. We provide market information across the developed and emerging markets

  • ADHERING TO QUICK DELIVERY TIME LINES

    We provide impeccable research reports in quick turnaround time

Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018


 

Available formats:    

StumbleUponEmail

Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment

 

Overview:

Duchenne muscular dystrophy is a genetic disorder which causes progressive muscle degeneration and weakness, and it is one of the nine types of muscular dystrophy. Duchenne muscular dystrophy mostly affects males, but in rare cases occurs in females. Onset of the disease is generally 3 to 4 years of age and begins on hips, pelvic region, shoulders, and upper legs. Symptoms may include delayed or difficulty inability to stand, walk and difficulty in speaking.

Disease is diagnosed through the patient history, blood test for creatinine phosphokinase levels, molecular genetic testing, and muscle biopsy. There is no cure available for the disease till now. But the medications are available forrelieving the symptoms of the disease. Eteplirsen is used to treat the patients with specific gene mutation of gene that leads to DMD. Deflazacort, approved in 2017, becoming first corticosteroid to treat Duchenne muscular dystrophy.

 

Segmentation:

By formulation, Duchenne muscular dystrophy pipeline drugs are segmented into

  • Oral
  • Parenteral
  • Others

By therapy, Duchenne muscular dystrophy pipeline drugs are segmented into

  • Exon Skipping
  • Gene Therapy
  • Corticosteroids
  • Others

By trial phase, Duchenne muscular dystrophy pipeline drugs are segmented into

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By company, Duchenne muscular dystrophy pipeline drugs are segmented into

  • Pfizer Inc. (U.S.)
  • ReveraGenBioPharma, Inc. (U.S.)
  • Sarepta Therapeutics Inc. (U.S.)
  • Daiichi Sankyo Company (Japan)
  • BioMarin Pharmaceutical Inc. (U.S.)
  • NS Pharma, Inc. (Japan)
  • TAIHO PHARMACEUTICAL CO. (Japan)

 

Space Analysis:

Until the approval of exon skipping agent eteplirsen, carticostroids are the only potential treatment for the treatment of duchenne muscular atrophy, but with many side effects. Duchenne muscular dystrophy pipeline has the robust drug molecules and therapies such as gene therapy, exon skipping agents and also promising corticosteroids for the treatment. Furthermore, Catabasis Pharmaceuticals has been developing NF-kB protein inhibitor in phase-II development to treat duchenne muscular dystrophy. Moreover, there are numerous early stage development of drugs including, drugs which targets calcium regulation, fibrosis and oxidative stress.

  • In November 2016, Wave Life Sciences Ltd. Initiated the Phase I clinical trial for WVE-210201 Duchenne muscular dystrophy patients amenable to exon 51 skipping.

 

Report Description:

Duchenne Muscular Dystrophy Pipeline Drugs Assessment report studies the various therapeutics under clinical development for XYX treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Duchenne muscular dystrophy pipeline drugsdevelopment. This report studies the dynamics of the Duchenne Muscular Dystrophy Pipeline Drugs i.e. drivers, challenges,andopportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Duchenne muscular dystrophy pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis onthe each drug candidates in the clinical trial phases

 

  1. Executive Summary
  2. Global Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market Introduction
    • Global Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market – Taxonomy
    • Global Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market –Definitions
      • Formulation
      • Therapy
      • Trial Phase
  1. Global Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market Dynamic Factors – Impact Analysis
    • Global Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market – Competition Landscape
    • Epidemiology
  2. Global Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024
    • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market OpportunityAnalysis
  3. Global Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market, By Formulation, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Oral
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Parenteral
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market Forecast, By Therapy,2013 – 2017 and Forecast, 2018 – 2024
    • Exon Skipping
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Gene Therapy
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Corticosteroids
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market Forecast, By Trial Phase,2013 – 2017 and Forecast, 2018 – 2024
    • Phase I
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase II
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase III
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase IV
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Formulation, By Therapy, By Trial Phase, and Region, 2018 – 2024
  2. North America Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment MarketAnalysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Formulation Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Parenteral
      • Others
    • Therapy Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Exon Skipping
      • Gene Therapy
      • Corticosteroids
      • Others
    • Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Phase I
      • Phase II
      • Phase III
      • Phase IV
    • Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • S.
      • Canada
    • North America Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Formulation, By Therapy, By Trial Phase, and Country, 2018 – 2024
    • North America Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market Dynamics – Trends
  3. Europe Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Formulation Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Parenteral
      • Others
    • Therapy Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Exon Skipping
      • Gene Therapy
      • Corticosteroids
      • Others
    • Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Phase I
      • Phase II
      • Phase III
      • Phase IV
    • Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Formulation, By Therapy, By Trial Phase, and Country, 2018 – 2024
    • Europe Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market Dynamics – Trends
  4. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Formulation Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Parenteral
      • Others
    • Therapy Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Exon Skipping
      • Gene Therapy
      • Corticosteroids
      • Others
    • Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Phase I
      • Phase II
      • Phase III
      • Phase IV
    • Country Analysis2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Formulation, By Therapy, By Trial Phase, and Country, 2018 – 2024
    • Asia-Pacific Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market Dynamics – Trends
  5. Latin America Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Formulation Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Parenteral
      • Others
    • Therapy Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Exon Skipping
      • Gene Therapy
      • Corticosteroids
      • Others
    • Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Phase I
      • Phase II
      • Phase III
      • Phase IV
    • Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Formulation, By Therapy, By Trial Phase, and Country, 2018 – 2024
    • Latin America Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market Dynamics – Trends
  6. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Formulation Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Parenteral
      • Others
    • Therapy Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Exon Skipping
      • Gene Therapy
      • Corticosteroids
      • Others
    • Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Phase I
      • Phase II
      • Phase III
      • Phase IV
    • Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Formulation, By Therapy, By Trial Phase, and Country, 2018 – 2024
    • MEA Duchenne Muscular Dystrophy (DMD) Pipeline Drugs Assessment Market Dynamics – Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Formulation& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Pfizer Inc. (U.S.)
      • ReveraGenBioPharma, Inc. (U.S.)
      • Sarepta Therapeutics Inc. (U.S.)
      • Daiichi Sankyo Company (Japan)
      • BioMarin Pharmaceutical Inc. (U.S.)
      • NS Pharma, Inc. (Japan)
      • TAIHO PHARMACEUTICAL CO. (Japan)
  1. Research Methodology
  2. Key Assumptions and Acronyms

 

Disclaimer

The above mentioned segmentation is tentative; it is changed according to client’s requirement, or research feasibility.

 

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Avail Discount  Up To 20%

Need more discount on this report?

Call or e-mail us for:

(U.S.) – +1-866-598-1553

Contact SalesTOLL FREE: +1-866-598-1553